Trial Profile

Phase II Study of Raltegravir as Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Based Antiretroviral Therapy in Women With Fat Accumulation

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Raltegravir (Primary) ; HIV protease inhibitors; Non-nucleoside reverse transcriptase inhibitors
Indications HIV-1 infections
Focus Adverse reactions
Acronyms IISP-Raltegravir

16 Feb 2017 Results (n=37) assessing effect of switching from protease and non-nucleotide reverse transcriptase inhibitors-based regimens to raltegravir-based regimens on biomarkers of liver steatosis and metabolic syndrome in women, presented at the 24th Conference on Retroviruses and Opportunistic Infections.
06 Mar 2013 Biomarker results presented at the 20th Conference on Retroviruses and Opportunistic Infections.
20 Jul 2011 Results presented at the 6th International AIDS Society Conference on HIV Pathogenesis and Treatment.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com